613 related articles for article (PubMed ID: 34504767)
1. Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia.
Bedier H; Lin J; Frenette C; Routy JP
IDCases; 2021; 26():e01263. PubMed ID: 34504767
[TBL] [Abstract][Full Text] [Related]
2. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Arthurs B; Wunderle K; Hsu M; Kim S
Respir Med Case Rep; 2017; 21():27-29. PubMed ID: 28377877
[TBL] [Abstract][Full Text] [Related]
3. Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report.
Le TH; Kumar V; Gondal K; Barnes M; Siddique H; Buttar B; Kaell A
BMC Infect Dis; 2020 Feb; 20(1):175. PubMed ID: 32093604
[TBL] [Abstract][Full Text] [Related]
4. Invasive Fungal Infection Complicating Treatment With Ibrutinib.
Rajapakse P; Gupta M; Hall R
Cureus; 2021 Jun; 13(6):e16009. PubMed ID: 34336499
[TBL] [Abstract][Full Text] [Related]
5. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S
J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683
[TBL] [Abstract][Full Text] [Related]
6. Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Alkharabsheh O; Alsayed A; Morlote DM; Mehta A
Curr Oncol; 2021 Feb; 28(1):837-841. PubMed ID: 33567487
[TBL] [Abstract][Full Text] [Related]
7. A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.
Eichenberger EM; Saullo J; Brander D; Wang SH; Perfect JR; Messina JA
Med Mycol Case Rep; 2020 Mar; 27():17-21. PubMed ID: 31879587
[TBL] [Abstract][Full Text] [Related]
8. [Elderly chronic lymphocytic leukemia combined with invasive aspergillosis infection in one case].
Li BL; Li SX; Wang TM; Zhu HL; Wang HT; Li J; Liu Y; Zhai B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):99-105. PubMed ID: 25687054
[TBL] [Abstract][Full Text] [Related]
9. Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy.
Voshtina E; Huang H; Raj R; Atallah E
Case Rep Hematol; 2018; 2018():6514604. PubMed ID: 30155323
[TBL] [Abstract][Full Text] [Related]
10. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Kreiniz N; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
[TBL] [Abstract][Full Text] [Related]
12. A case report of the metagenomics next-generation sequencing for early detection of central nervous system mucormycosis with successful rescue in patient with recurrent chronic lymphocytic leukemia.
Zhang J; Luo J; Weng X; Zhu Y; Goyal G; Perna F; Espinoza-Gutarra M; Jiang L; Chen L; Mi JQ
Ann Transl Med; 2022 Jun; 10(12):722. PubMed ID: 35845522
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Gordon MJ; Danilov AV
Ther Adv Hematol; 2021; 12():2040620721989588. PubMed ID: 33796237
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Burger JA; Sivina M; Jain N; Kim E; Kadia T; Estrov Z; Nogueras-Gonzalez GM; Huang X; Jorgensen J; Li J; Cheng M; Clow F; Ohanian M; Andreeff M; Mathew T; Thompson P; Kantarjian H; O'Brien S; Wierda WG; Ferrajoli A; Keating MJ
Blood; 2019 Mar; 133(10):1011-1019. PubMed ID: 30530801
[TBL] [Abstract][Full Text] [Related]
15. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature.
Fehr M; Cathomas G; Graber A; Makert E; Gaus E; Boggian K
Med Mycol Case Rep; 2020 Mar; 27():14-16. PubMed ID: 31890489
[TBL] [Abstract][Full Text] [Related]
16. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
Front Immunol; 2020; 11():2158. PubMed ID: 32983178
[TBL] [Abstract][Full Text] [Related]
17. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
20. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
